A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

ClinicalTrials.gov ID

NCT05999994

Lead Sponsor

Eli Lilly and CompanyINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

105Estimated

Last Update Posted

Aug 7, 2026Actual

Start Date

Jan 22, 2020Actual

Primary Completion Date

May 2027Estimated

Completion Date

May 2027Estimated

Official Title

CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research

Brief Summary

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.

• Neoplasms
• Child
• Adolescent

• Ramucirumab
• Cyclophosphamide
• Vinorelbine
• Gemcitabine
• Docetaxel
• Abemaciclib
• Irinotecan
• Temozolomide

Ages Eligible for Study

Child (0-17)Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Participants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll.

• Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
• The participant has a Lansky (<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50.
• Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 days after the last dose and must have recovered from clinically significant side effects.
• The participant has adequate hematologic and organ function.
• Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose.
• Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug.

Participants will be ineligible if they meet any of the exclusion criteria below. Additional criteria are specified in the protocol amendment to which the participant will enroll.

• Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol.
• Participants who have active infections requiring therapy.
• Participants who have had allogeneic bone marrow or solid organ transplant.
• Participants who have had, or are planning to have, certain invasive procedures.
• Female participants who are pregnant or breastfeeding.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Eli Lilly and CompanyINDUSTRY

3227642376

33478785126

+33478782642

33144324068

492017232255

4940741020622

390516366411

39022393062

390668592444

81120023812

81120023812

81120023812

31650006353

34932532100

34955012593

• CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

  NCT04145349

  CompletedInterventionalPhase 1Phase 2Updated Aug 7, 2026
• CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

  NCT04145700

  TerminatedInterventionalPhase 1Phase 2Updated Sep 13, 2023
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  NCT02154490

  CompletedObservationalUpdated Jun 1, 2023
• CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

  NCT05440786

  Active, not recruitingInterventionalPhase 2Updated Apr 13, 2026
• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463

  TerminatedInterventionalPhase 1Updated Mar 5, 2026
• A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

  NCT02745769

  CompletedInterventionalPhase 1Updated Mar 5, 2019